Evans E R, Wallace M G
Curr Med Res Opin. 1975;3(3):132-7. doi: 10.1185/03007997509113660.
In a multi-centre trial of mazindol ('Teronac'), a new anorectic agent unrelated to amphetamine, 274 male and female patients were treated by 53 investigators in Eire. All patients were overweight according to the Metropolitan Life Assurance Company Tables, and 166 patients completed the treatment regime of one 2 mg. tablet daily and a 100 calorie diet for 12 weeks. The average weight loss was 18.8 lbs. (8.5 kg.); 85% of patients reported good appetite supression and good ability to adhere to their diet, and the attending physicians rated mazindol as being of considerable help in 92% of the patients. Mazindol was well tolerated, only 29 patients dropped out of the trial because of side-effects.
在一项关于新型食欲抑制剂马吲哚（“Teronac”）的多中心试验中，该药物与苯丙胺无关，爱尔兰的53名研究人员对274名男性和女性患者进行了治疗。根据大都会人寿保险公司的表格，所有患者均超重，166名患者完成了每日服用一片2毫克片剂并搭配100卡路里饮食的治疗方案，为期12周。平均体重减轻了18.8磅（8.5千克）；85%的患者表示食欲得到了良好抑制，并且能够很好地坚持饮食，主治医生认为马吲哚对92%的患者有很大帮助。马吲哚耐受性良好，只有29名患者因副作用退出试验。
